| [1] |
Brouwer S, Rivera-Hernandez T, Curren BF, et al. Pathogenesis, epidemiology and control of Group A Streptococcus infection. Nat Rev Microbiol, 2023; 21, 431−47. doi: 10.1038/s41579-023-00865-7 |
| [2] |
Lamagni T, Guy R, Chand M, et al. Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study. Lancet Infect Dis, 2018; 18, 180−7. doi: 10.1016/S1473-3099(17)30693-X |
| [3] |
Hurst JR, Brouwer S, Walker MJ, et al. Streptococcal superantigens and the return of scarlet fever. PLoS Pathogens, 2021; 17, e1010097. doi: 10.1371/journal.ppat.1010097 |
| [4] |
Ceylan Z. Estimation of COVID-19 prevalence in Italy, Spain, and France. Sci Total Environ, 2020; 729, 138817. doi: 10.1016/j.scitotenv.2020.138817 |
| [5] |
Wu WW, Li Q, Tian DC, et al. Forecasting the monthly incidence of scarlet fever in Chongqing, China using the SARIMA model. Epidemiol Infect, 2022; 150, e90. doi: 10.1017/S0950268822000693 |
| [6] |
Veenstra JQ. Persistence and anti-persistence: theory and software. Western University. 2013. |
| [7] |
Liu YH, Ding H, Chang ST, et al. Exposure to air pollution and scarlet fever resurgence in China: a six-year surveillance study. Nat Commun, 2020; 11, 4229. doi: 10.1038/s41467-020-17987-8 |
| [8] |
Kim JH, Cheong HK. Increasing number of scarlet fever cases, South Korea, 2011-2016. Emerg Infect Dis, 2018; 24, 172−3. doi: 10.3201/eid2401.171027 |
| [9] |
You YH, Davies MR, Protani M, et al. Scarlet fever epidemic in China caused by Streptococcus pyogenes serotype M12: epidemiologic and molecular analysis. EBioMedicine, 2018; 28, 128−35. doi: 10.1016/j.ebiom.2018.01.010 |
| [10] |
Staszewska-Jakubik E, Czarkowski MP, Kondej B. Scarlet fever in Poland in 2014. Przegl Epidemiol, 2016; 70, 195−202. |